ESTRO 2025 - Abstract Book

S1116

Clinical – Head & neck

ESTRO 2025

4136

Digital Poster Impact of sarcopenia on acute toxicity for head and neck cancer patients treated with hadrontherapy: a prospective study (NCT06207708) Rossana Ingargiola 1 , Anna Maria Camarda 1 , Carmine Tinelli 2 , Nadia Facchinetti 3 , Federica Serra 3 , Viola Ghio 3 , Barbara Vischioni 1 , Sara Ronchi 1 , Maria Bonora 1 , Alessia Bazani 4 , Stefania Russo 4 , Eleonora Rossi 4 , Ester Orlandi 1,5 1 Radiation Oncology Unit, Clinical Department, CNAO National Center for Oncological Hadrontherapy, Pavia, Italy. 2 Scientific Direction, CNAO National Center for Oncological Hadrontherapy, Pavia, Italy. 3 Clinical Trial Center, CNAO National Center for Oncological Hadrontherapy, Pavia, Italy. 4 Medical Physics Unit, Clinical Department, CNAO National Center for Oncological Hadrontherapy, Pavia, Italy. 5 Department of Clinical, Surgical, Diagnostic, and Pediatric Sciences, University of Pavia, Pavia, Italy Purpose/Objective: Sarcopenia (SP) has been associated with higher toxicity in patients treated with photon-based radiotherapy (RT) and chemotherapy 1 . However, evidence on head and neck cancer (HNC) patients are still lack and no data are available on patients treated with particle therapy 2 . We aimed to evaluate the impact of SP on acute toxicity in HNC patients treated with particle therapy. We also investigate a possible association between SP and nutritional profile assessed by Mini Nutritional Assessment Short Form (MNA-SF) and the Nutritional Risk Screening 2002 (NRS-2002); BMI and fatigue (EORTC QLQ-FA12 questionnaire). Material/Methods: We prospectively analysed 70 HNC patients treated with definitive/postoperative particle therapy (proton or carbon ions) with/without chemotherapy at CNAO. SP was defined by contoured the skeletal muscles tissue at the C3 level 3 on the CT scan simulation and evaluation performed during treatment (figure 1). The cut-off values of sarcopenia were established at skeletal muscle index < 42.4 cm2/m2 (men) and < 30.6 cm2/m2 (women).Toxicity was weekly assessed according to National Cancer Institute’s Common Terminology Criteria for Adverse Events CTCAE (version 5.0). The MNA-SF, NRS-2002 score and EORTC QLQ-FA12 questionnaire were administered before treatment start. BMI was evaluated at baseline, during and at the end of the treatment. Descriptive statistics was calculated for categorical variables. To investigate association between sarcopenia and acute toxicity, risk of malnutrition and fatigue was used a chi square test or Fisher's exact test, as appropriate. To examine association between SP and BMI t-test for independent data was used.